Items Tagged ‘fluorouracil’

February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

By

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe […]

View full entry

Tags: Anal Cancer, Breast Cancer, capecitabine, Colon Cancer, fda, fluorouracil, Gastric Cancer, Gastrointestinal Stromal Tumors, life-threatening, Liver Cancer, News, Pancreatic Cancer


November 3rd, 2015

Onivyde Approved for Pancreatic Cancer

By

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with pancreatic cancer that has spread to distant sites in the body who have received prior treatment with the chemotherapy agent, […]

View full entry

Tags: advanced, fluorouracil, irinotecan liposome injection, leucovorin, News, Onivyde, Pancreatic Cancer, Stage IV Pancreatic Cancer


April 30th, 2015

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer

By

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released online by the journal The Lancet. Node-positive breast cancer means that cancer cells from the breast have been found in the lymph nodes under the arm. Although […]

View full entry

Tags: Breast Cancer, cyclophosphamide, Cytoxan, early-stage, Ellence, epirubicin, fluorouracil, News, node-positive, paclitaxel, Stages II-III Breast Cancer, Taxol